Is Crispr Therapeutics AG (CRSP) overvalued? · rev $11.6M
Crispr Therapeutics AG (CRSP) is a biotechnology company listed on US.
This page asks whether Crispr Therapeutics AG (CRSP) looks expensive on cached numbers — not a short thesis.
Latest reported CRSP revenue for 2026-06-30 was $11.6M. Net income was -$214.1M. CRSP currently screens at market cap $5.42B.
CRSP currently screens at market cap $5.42B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CRSP 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CRSP stock page for the full model, not this heading.
Not investment advice.